Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | SNCA | P37840 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9330371 | 1.00 | MAPT (0.54) | MAPTPGRHTR1AADORA3PTGS1 | |
| SCHEMBL6551812 | 1.00 | MAPT (0.54) | MAPTPGRHTR1AADORA3PTGS1 | |
| SCHEMBL6551817 | 1.00 | MAPT (0.54) | MAPTPGRHTR1AADORA3PTGS1 | |
| SCHEMBL9330335 | 0.98 | MAPT (0.52) | MAPTPGRHTR1AADORA3PTGS1 | |
| SCHEMBL9330325 | 0.98 | MAPT (0.52) | MAPTPGRHTR1AADORA3PTGS1 | |
| SCHEMBL4017572 | 0.84 | ALDH1A1 (0.55) | MAPTDRD3CYP3A4ALDH1A1ALOX15 | |
| SCHEMBL13142549 | 0.80 | KMT2A (0.53) | MAPTCYP3A4ALDH1A1ALOX15LMNA | |
| SCHEMBL21744525 | 0.80 | ALDH1A1 (0.50) | MAPTDRD3ALDH1A1ALOX15POLB | |
| SCHEMBL1973155 | 0.80 | ALDH1A1 (0.50) | MAPTDRD3ALDH1A1ALOX15POLB | |
| SCHEMBL1973157 | 0.80 | ALDH1A1 (0.50) | MAPTDRD3ALDH1A1ALOX15POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227811-A1 | FARNESYLAMINE DERIVATIVES AND METHODS OF USE | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2008143947-A1 | FARNESYLAMINE DERIVATIVES AND METHODS OF USE | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-11-27 | — | — | WO | claimed |
| US-20100227811-A1 | FARNESYLAMINE DERIVATIVES AND METHODS OF USE | UNIVERSITY OF SOUTH FLORIDA (US) | 2010-09-09 | — | — | US | disclosed |
| WO-2009029762-A2 | FARNESYLAMINE INHIBITORS OF THE VISUAL CYCLE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2008143947-A1 | FARNESYLAMINE DERIVATIVES AND METHODS OF USE | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2006086372-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL SYMPTOMS ASSOCIATED WITH ALCOHOL-WITHDRAWAL AND FOR CONVULSIVE SEIZURE | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2006-08-17 | — | — | WO | disclosed |
| US-5273969-A | A phosphonylmethylphosphoalkylaminoalkane derivative | E. R. SQUIBB & SONS, INC. (US) | 1993-12-28 | — | — | US | disclosed |
| US-5212164-A | Hypocholesterolemic and antiatherosclerotic agents | E. R. SQUIBB & SONS, INC. (US) | 1993-05-18 | — | — | US | disclosed |
| EP-0356866-A2 | Phosphorus-containing squalene synthetase inhibitors and method | E.R. SQUIBB & SONS, INC. (US) | 1990-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227811-A1 | FARNESYLAMINE DERIVATIVES AND METHODS OF USE | RAF1, NRAS, KSR1 | MAPT 4829/4885PGR 4585/4885HTR1A 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.